Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.33 |
| ▸ | TYK2 | P29597 | 7/20 | 0.33 |
| ▸ | JAK3 | P52333 | 7/20 | 0.33 |
| ▸ | JAK1 | P23458 | 6/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773011 | 0.93 | CTSK (0.34) | JAK2TYK2JAK3JAK1SPR | |
| SCHEMBL15608004 | 0.89 | TACR3 (0.36) | JAK2TYK2JAK3JAK1SPR | |
| SCHEMBL13738872 | 0.89 | TACR3 (0.36) | JAK2TYK2JAK3JAK1SPR | |
| SCHEMBL13738996 | 0.89 | TACR3 (0.36) | JAK2TYK2JAK3JAK1SPR | |
| SCHEMBL3720967 | 0.82 | JAK2 (0.33) | JAK2TYK2JAK3JAK1SPR | |
| SCHEMBL18711854 | 0.82 | JAK2 (0.43) | JAK2TYK2JAK3JAK1 | |
| SCHEMBL28077869 | 0.81 | HSD11B1 (0.31) | JAK2JAK1 | |
| SCHEMBL1772783 | 0.81 | ITGB3 (0.36) | ITGB3ITGA2BMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6195337 | 0.81 | JAK2 (0.32) | JAK2TYK2JAK3JAK1SPR | |
| SCHEMBL1581772 | 0.80 | ITGB3 (0.34) | TACR3ITGB3ITGA2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758051-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | claimed |
| WO-2013043962-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | claimed |
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | claimed |
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER | 2006-01-05 | — | — | US | claimed |
| CN-107148420-A | Benzyl substituted indazoles | 拜耳制药股份公司 | 2017-09-08 | — | — | CN | disclosed |
| EP-2492266-B1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| EP-2758051-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8785462-B2 | 5-hydroxypyrimidine-4-carboxamide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8765771-B2 | Condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same | KOWA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2586781-A1 | NOVEL CONDENSED PYRIDINE OR CONDENSED PYRIMIDINE DERIVATIVE, AND MEDICINAL AGENT COMPRISING SAME | KOWA CO. LTD. (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102621-A1 | NOVEL CONDENSED PYRIDINE OR CONDENSED PYRIMIDINE DERIVATIVE, AND MEDICINAL AGENT COMPRISING SAME | KOWA CO., LTD. (JP) | 2013-04-25 | — | — | US | disclosed |
| WO-2013043962-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6521754-B2 | Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isoni cotinamide | HOFFMAN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| US-6355655-B1 | TREATING A COGNITIVE DISORDER, A NEURO-DEGENERATIVE DISORDER; AGE-RELATED DEMENTIA; AGE-INDUCED MEMORY IMPAIRMENT; A MOVEMENT DISORDER, ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER; PSYCHOSIS; COGNITIVE DEFICITS | ELI LILLY AND COMPANY | 2002-03-12 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
| EP-1100498-A4 | HETEROCYCLIC SULPHONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1100498-A1 | HETEROCYCLIC SULPHONAMIDE DERIVATIVES | Eli Lilly & Company (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006159-A1 | HETEROCYCLIC SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | JAK2 908/4885TYK2 2879/4885JAK3 2422/4885 |
| US-20130102621-A1 | NOVEL CONDENSED PYRIDINE OR CONDENSED PYRIMIDINE DERIVATIVE, AND MEDICINAL AGENT COMPRISING SAME | IAPP, GPR119, RNASE1 | JAK2 365/4885TYK2 3587/4885JAK3 1335/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | JAK2 908/4885TYK2 2879/4885JAK3 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.